Skip to main content

Table 1 General characteristics of the animal model (mean ± SEM)

From: Erythropoietin attenuates cardiac dysfunction by increasing myocardial angiogenesis and inhibiting interstitial fibrosis in diabetic rats

Parameters Controls (n = 8) DM rats (n = 8) DM + EPO rats (n = 8)
LVD d (mm) 6.62 ± 0.36 7.48 ± 0.72* 6.78 ± 0.53
LVD s (mm) 3.57 ± 0.58 4.65 ± 0.74* 3.67 ± 0.65
EF (%) 79.4 ± 8.12 65.7 ± 5.49# 75.6 ± 4.87
Body weight (g) baseline 236 ± 7.9 241 ± 6.7 239 ± 8.8
Body weight (g) end-point 358 ± 13.8 293 ± 13.5# 332 ± 15.4
Heart rate (BPM) 411.8 ± 46.8 416.6 ± 67.2 376.9 ± 43.0
HW/BW (mg/g) 3.1 ± 0.14 4.5 ± 0.20# 3.3 ± 0.18
Blood glucose (mmol/L) baseline 4.55 ± 0.60 20.47 ± 1.46# 20.63 ± 1.62#
Blood glucose (mmol/L) end-point 4.13 ± 0.43 20.27 ± 1.20# 21.37 ± 1.53#
Erythrocyte numbers (1012/L) baseline 8.00 ± 0.43 7.84 ± 0.40 8.06 ± 0.23
Erythrocyte numbers (1012/L) end-point 8.16 ± 0.37 7.68 ± 0.34 8.23 ± 0.47
  1. *P < 0.05 vs control, #P <0.01 vs control, P <0.05 vs diabetes.